Abata News

Abata Therapeutics to Present at Upcoming Investor and Industry Events in June

Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer

We Now Know the Enemy: A Conversation with Richard Ransohoff, M.D. Featuring John Maraganore, Ph.D.

Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity

Trends in Immunology

Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors

December 14, 2022

Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis

December 7, 2022

Abata Therapeutics Appoints Ellen Cahir-McFarland, Ph.D., as Chief Scientific Officer

November 9, 2022

Abata Therapeutics to Participate in Guggenheim’s 4th Annual Immunology and Neurology Day

September 8, 2022

Samantha Singer Named as 2022 PharmaVoice 100 Honoree